Lycia Therapeutics (NASDAQ:LYCA) Now Covered by Analysts at Evercore

Research analysts at Evercore assumed coverage on shares of Lycia Therapeutics (NASDAQ:LYCA – Get Free Report) in a research report issued to clients and investors on Tuesday, Briefing.com reports. The firm set an “outperform” rating and a $43.00 price target on the stock. Evercore‘s price objective would suggest a potential upside of 50.30% from the company’s current price.

A number of other brokerages have also commented on LYCA. Jefferies Financial Group began coverage on shares of Lycia Therapeutics in a report on Tuesday. They issued a “buy” rating and a $50.00 price objective on the stock. Wall Street Zen raised Lycia Therapeutics to a “hold” rating in a report on Saturday, October 31st. Four research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $56.00.

Read Our Latest Stock Analysis on LYCA

Lycia Therapeutics Stock Performance

Shares of LYCA stock opened at $28.61 on Tuesday. Lycia Therapeutics has a twelve month low of $22.19 and a twelve month high of $36.49.

Insider Buying and Selling

In related news, major shareholder Venrock Healthcare Capital Par bought 1,952,705 shares of the company’s stock in a transaction on Monday, October 26th. The shares were purchased at an average cost of $18.04 per share, with a total value of $35,226,798.20. Following the completion of the transaction, the insider directly owned 6,785,437 shares of the company’s stock, valued at approximately $122,409,283.48. This represents a 40.41% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders acquired 2,078,749 shares of company stock worth $38,526,342.

Lycia Therapeutics Company Profile

(Get Free Report)

Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.

Further Reading

Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.